Delgocitinib Topical Dosage

Usual Adult Dose for Eczema

Apply a thin layer topically twice a day to affected areas of the hands and wrists only.

• Do not use more than 30 grams per 2 weeks OR 60 grams per month.

Comments:

• Prior to cream application, the affected areas should be cleaned and dried.
• Limitations of use: Not recommended in combination with other Janus kinase (JAK) inhibitors or potent immunosuppressants.

Use: For the topical treatment of moderate to severe chronic hand eczema in patients who have had an inadequate response to, or for whom topical corticosteroids are not advisable

Renal Dose Adjustments

Renal dysfunction: Data not available

Liver Dose Adjustments

Liver dysfunction: Data not available

Precautions

US FDA requires a medication guide to assure safe use. For additional information visit:
www.fda.gov/drugs/drug-safety-and-availability/medication-guides

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For topical use on hands and wrists only; not for oral, ophthalmic, or intravaginal use.
• Before therapy, complete any necessary immunizations, including herpes zoster vaccinations, according to current immunization guidelines.
• During application, avoid contact with eyes, mouth, or other mucous membranes; rinse thoroughly with water if contact occurs.

Storage requirements:

• Store product at 20C to 25C (68F to 77F); excursions permitted from 15C to 30C (59F to 86F).
• Do not freeze.

General:

• Avoid use of this drug in patients with active or serious infections.
• Live vaccines should be avoided immediately prior to, during, and immediately after treatment.
• Use of sunscreen and/or protective clothing is recommended during therapy to minimize sun exposure.

Monitoring:

• Dermatologic: Examination of application site(s), especially in patients at risk of skin cancer (during therapy)
• Infections: For signs/symptoms of infection (during and after therapy); for reactivation of viral hepatitis (before and during therapy)

Patient advice:

• Read the US FDA-approved patient labeling (Medication Guide).
• Do not use more than 30 grams per 2 weeks or 60 grams per month.
• Contact your health care provider immediately if any signs or symptoms of infection occur.
• Inform your provider if you have experienced any type of cancer.
• Understand periodic skin examinations will be performed during therapy; avoid sunlamps and minimize sun exposure by using sunscreen and protective clothing.
• Avoid the use of live vaccines immediately before, during, and immediately after therapy.
• Speak to a healthcare provider if you are pregnant, intend to become pregnant, or are breastfeeding.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer